Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a notable advancement for weight treatment. Early patient trials https://mediajx.com/story28058689/the-retatru-tide-substance-the-innovation-in-body-control